Ninh M. La‐Beck

2.4k total citations · 1 hit paper
43 papers, 1.8k citations indexed

About

Ninh M. La‐Beck is a scholar working on Oncology, Biomaterials and Biomedical Engineering. According to data from OpenAlex, Ninh M. La‐Beck has authored 43 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 18 papers in Biomaterials and 12 papers in Biomedical Engineering. Recurrent topics in Ninh M. La‐Beck's work include Nanoparticle-Based Drug Delivery (18 papers), Nanoplatforms for cancer theranostics (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Ninh M. La‐Beck is often cited by papers focused on Nanoparticle-Based Drug Delivery (18 papers), Nanoplatforms for cancer theranostics (12 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Ninh M. La‐Beck collaborates with scholars based in United States, Israel and United Kingdom. Ninh M. La‐Beck's co-authors include Alberto Gabizón, Saeed K Alzghari, Yogita P. Patil, Gary W. Jean, Devin B. Lowe, Cindy Huynh, Laurence M. Wood, Xinli Liu, Hilary Shmeeda and Maciej M. Markiewski and has published in prestigious journals such as Journal of Clinical Oncology, ACS Nano and The Journal of Immunology.

In The Last Decade

Ninh M. La‐Beck

42 papers receiving 1.8k citations

Hit Papers

Thirty years from FDA app... 2025 2026 2025 10 20 30
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective
    2025 33 citations Alberto Gabizón, Ninh M. La‐Beck et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ninh M. La‐Beck United States 19 766 634 603 504 349 43 1.8k
Leaf Huang United States 25 743 1.0× 691 1.1× 1.2k 2.0× 313 0.6× 481 1.4× 45 2.2k
Lei Yu China 32 495 0.6× 663 1.0× 1.1k 1.9× 982 1.9× 460 1.3× 104 2.7k
Xiaoxue Xie China 28 492 0.6× 713 1.1× 637 1.1× 330 0.7× 263 0.8× 75 1.9k
Edgar Pérez‐Herrero Spain 16 771 1.0× 760 1.2× 707 1.2× 252 0.5× 130 0.4× 21 1.9k
Run Lin China 19 394 0.5× 413 0.7× 383 0.6× 390 0.8× 360 1.0× 46 1.5k
Marta Truffi Italy 24 405 0.5× 394 0.6× 704 1.2× 379 0.8× 155 0.4× 69 1.7k
Imran Vhora India 21 617 0.8× 386 0.6× 877 1.5× 325 0.6× 111 0.3× 25 1.8k
Lacey R. McNally United States 27 358 0.5× 819 1.3× 668 1.1× 341 0.7× 207 0.6× 79 2.0k
François Fay United States 21 611 0.8× 553 0.9× 569 0.9× 119 0.2× 362 1.0× 39 1.7k
Shuang Cai China 23 370 0.5× 335 0.5× 815 1.4× 309 0.6× 201 0.6× 60 1.8k

Countries citing papers authored by Ninh M. La‐Beck

Since Specialization
Citations

This map shows the geographic impact of Ninh M. La‐Beck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ninh M. La‐Beck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ninh M. La‐Beck more than expected).

Fields of papers citing papers by Ninh M. La‐Beck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ninh M. La‐Beck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ninh M. La‐Beck. The network helps show where Ninh M. La‐Beck may publish in the future.

Co-authorship network of co-authors of Ninh M. La‐Beck

This figure shows the co-authorship network connecting the top 25 collaborators of Ninh M. La‐Beck. A scholar is included among the top collaborators of Ninh M. La‐Beck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ninh M. La‐Beck. Ninh M. La‐Beck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gabizón, Alberto, et al.. (2025). Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective. PubMed. 4(1). e000573–e000573. 33 indexed citations breakdown →
2.
La‐Beck, Ninh M., et al.. (2025). Identifying Oxysterols Associated With Age and Diet in Mice Using Optimized Reversed‐phase Liquid Chromatography‐Mass Spectrometry (RPLC‐MS). Journal of Separation Science. 48(10). e70274–e70274. 2 indexed citations
3.
Qiu, Lingxiao, Chen Zhao, Xinye Zhang, et al.. (2024). MS4A15 gene expression as a prognostic marker for clinical outcomes in lung adenocarcinoma. Translational Lung Cancer Research. 14(1). 224–238.
4.
Gabizón, Alberto, Hilary Shmeeda, Benjamin Draper, et al.. (2023). Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes. Pharmaceutics. 15(11). 2606–2606. 3 indexed citations
5.
6.
La‐Beck, Ninh M., et al.. (2020). Optimizing Patient Outcomes with PD‐1/PD‐L1 Immune Checkpoint Inhibitors for the First‐Line Treatment of Advanced Non–Small Cell Lung Cancer. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 40(3). 239–255. 17 indexed citations
7.
Gabizón, Alberto, Rafael T. M. de Rosales, & Ninh M. La‐Beck. (2020). Translational considerations in nanomedicine: The oncology perspective. Advanced Drug Delivery Reviews. 158. 140–157. 40 indexed citations
8.
La‐Beck, Ninh M., et al.. (2019). Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines. Asia-Pacific Journal of Oncology Nursing. 6(2). 154–160. 75 indexed citations
9.
La‐Beck, Ninh M., et al.. (2019). Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment. Seminars in Cancer Biology. 68. 175–185. 35 indexed citations
10.
La‐Beck, Ninh M., Xinli Liu, & Laurence M. Wood. (2019). Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery. Frontiers in Pharmacology. 10. 220–220. 47 indexed citations
11.
La‐Beck, Ninh M. & Alberto Gabizón. (2017). Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy. Frontiers in Immunology. 8. 416–416. 79 indexed citations
12.
Anchordoquy, Thomas J., Yechezkel Barenholz, Diana Boraschi, et al.. (2017). Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions. ACS Nano. 11(1). 12–18. 256 indexed citations
13.
Le, Alexander, Saeed K Alzghari, Gary W. Jean, & Ninh M. La‐Beck. (2017). Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. Therapeutics and Clinical Risk Management. Volume 13. 223–236. 15 indexed citations
14.
Lowe, Devin B. & Ninh M. La‐Beck. (2016). Epithelial-mesenchymal transition as a potential biomarker for identifying responders to immune checkpoint inhibitor therapy in lung adenocarcinoma. Translational Cancer Research. 5(2). 208–210. 1 indexed citations
15.
Sabnani, Manoj K., et al.. (2016). Abstract 4008: Pegylated liposomal alendronate: The impact of the drug cargo on carrier-induced immune modulation. Cancer Research. 76(14_Supplement). 4008–4008. 1 indexed citations
16.
Gabizón, Alberto, Yogita P. Patil, & Ninh M. La‐Beck. (2016). New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resistance Updates. 29. 90–106. 195 indexed citations
17.
Alzghari, Saeed K, et al.. (2013). The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials. The Oncologist. 18(9). 1022–1031. 49 indexed citations
18.
La‐Beck, Ninh M., Beth A. Zamboni, Alberto Gabizón, et al.. (2011). Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemotherapy and Pharmacology. 69(1). 43–50. 96 indexed citations
19.
Dumond, Julie B., Manoli Vourvahis, Nardin Rezk, et al.. (2010). A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir. Clinical Pharmacology & Therapeutics. 87(6). 735–742. 48 indexed citations
20.
Song, Gina, et al.. (2010). Abstract 3700: Effect of gender on pharmacokinetic disposition of pegylated liposomal CKD-602 (S-CKD602) and optisomal topotecan (TLI) in rats. Cancer Research. 70(8_Supplement). 3700–3700. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leaf Huang Breakdown of academic impact, for papers by Lei Yu Breakdown of academic impact, for papers by Xiaoxue Xie Breakdown of academic impact, for papers by Edgar Pérez‐Herrero Breakdown of academic impact, for papers by Run Lin Breakdown of academic impact, for papers by Marta Truffi Breakdown of academic impact, for papers by Imran Vhora Breakdown of academic impact, for papers by Lacey R. McNally Breakdown of academic impact, for papers by François Fay Breakdown of academic impact, for papers by Shuang Cai
Rankless by CCL
2026